<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society clinical practice guideline.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Heber D, Greenway FL, Kaplan LM, Livingston E, Salvador J, Still C, Endocrine Society. Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010 Nov;95(11):4823-43. [248 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21051578&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Behavior therapy  (94.33); Diabetes with other coma, type I [juvenile type], not stated as uncontrolled  (250.31); Diabetes with other coma, type II or unspecified type, not stated as uncontrolled  (250.30); Gout, unspecified  (274.9); Hypoglycemia, unspecified  (251.2); Obesity, unspecified  (278.00); Unspecified disorder of lipoid metabolism  (272.9)"/><FieldValue Value="MSH: Absorptiometry, Photon ; Bariatric Surgery ; Behavior Therapy ; Blood Chemical Analysis ; Bone Density ; Diabetes Mellitus ; Diet ; Diet Therapy ; Dietary Proteins ; Dyslipidemias ; Exercise ; Fluid Therapy ; Gout ; Hypoglycemia ; Insulin ; Lipid Metabolism Disorders ; Minerals ; Nutritional Physiological Phenomena ; Obesity ; Outcome Assessment (Health Care) ; Patient Care Team ; Vitamins ; Weight Gain "/><FieldValue Value="MTH: Alkaline phosphatase measurement ; Behavior management ; Blood Chemical Analysis ; Bone Density ; Calcium measurement ; Diabetes Mellitus ; Diet ; Diet therapy ; Exercise ; Fluid Therapy ; Gout ; Hypoglycemia ; Insulin ; Insulin measurement ; Lipid Metabolism Disorders ; Minerals ; Nutrition management ; Obesity ; Parathyroid hormone measurement ; Patient Monitoring ; Phosphorus measurement ; Vitamin D measurement ; Vitamins ; Weight Gain "/><FieldValue Value="PDQ: hypoglycemia ; insulin ; obesity "/><FieldValue Value="SNOMEDCT_US: Alkaline phosphatase measurement  (88810008); Behavior management  (225333008); Behavioral therapy  (166001); Blood chemistry  (166312007); Calcium measurement  (71878006); Diabetes mellitus  (73211009); Dietary finding  (41829006); Dietary needs education  (370847001); Disorder of lipid metabolism  (267431006); Dyslipidemia  (370992007); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Food consistency types  (229961002); Gout  (90560007); Hypoglycemia  (237630007); Hypoglycemia  (271327008); Hypoglycemia  (302866003); Insulin  (39487003); Insulin  (412222002); Insulin  (67866001); Insulin measurement  (16890009); Mineral  (87918000); Monitoring of patient  (182777000); Nutrition management  (386372009); Obesity  (414915002); Obesity  (414916001); Parathyroid hormone measurement  (3352000); Phosphorus measurement  (8364005); Vitamin  (12968008); Vitamin  (87708000); Vitamin D measurement  (83729008); Weight gain  (161831008); Weight gain  (262286000); Weight gain  (8943002)"/><FieldValue Value="UMD: Densitometers, Bone, Isotope, Dual-Photon Absorptiometry  (17-150)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Obesity&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Gastroenterology" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nursing" /><FieldValue Value="Nutrition" /><FieldValue Value="Pharmacology" /><FieldValue Value="Surgery" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Dietitians" /><FieldValue Value="Nurses" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Psychologists/Non-physician Behavioral Health Clinicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To provide guidelines for the nutritional and endocrine management of adults after bariatric surgery, including those with diabetes mellitus&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients in the immediate postoperative period who have undergone bariatric surgery for obesity, including those with diabetes mellitus&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Formation of a multidisciplinary team &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Multidisciplinary treatment and evaluation, including diet instruction, increased activity, behavior modification, and pharmacologic therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evaluation of surgical outcome in cases of severe or unremitting postoperative weight gain &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Protein management &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vitamin and mineral supplementation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical and biochemical monitoring &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Postoperative glycemic control (including dextrose-free intravenous fluids and low-sugar liquid supplements)&amp;nbsp; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of insulin therapy for type 1 diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of lipid abnormalities according to the National Cholesterol Education Program (NCEP) guidelines &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Supplementation for patients who have undergone malabsorptive obesity surgical procedures&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Vitamin D, calcium, phosphorus, parathyroid hormone (PTH), and alkaline phosphatase levels&amp;nbsp;every 6 months &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Dual-energy x-ray absorptiometry for bone density annually &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prophylactic therapy for gout &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Initiation of oral fluids &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gradual progression of food consistency &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Continuous reinforcement of new nutritional habits &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evaluation for the possibility of insulin-mediated hypoglycemia in symptomatic patients &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Prevalence of weight loss and regain &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Improved psychological function, general health, quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adherence with dietary and lifestyle instructions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Changes in lean body mass &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of micro- and macronutritional deficiencies, gastric dumping syndrome, and refeeding syndrome &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Changes in clinical laboratory measures, including glycated hemoglobin (Hb) A1c, postprandial serum glucose, low-density lipoprotein cholesterol and triglyceride values &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Changes in bone mineral density &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Time to complications of surgery &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence and frequency of postsurgical vomiting and surgical complications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cardiovascular-related morbidity and mortality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Liver-related morbidity and mortality &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;PubMed was searched from 1980 to present. Search terms included bariatric surgery, obesity surgery, and post-surgical care.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;+OOO&lt;/strong&gt; Denotes very low quality evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;++OO&lt;/strong&gt; Denotes low quality evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;+++O&lt;/strong&gt; Denotes moderate quality evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;++++&lt;/strong&gt; Denotes high quality evidence&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Clinical Guidelines Subcommittee of The Endocrine Society deemed endocrine and nutritional management of the post-bariatric surgery patient a priority area in need of practice guidelines and appointed a Task Force to formulate evidence-based recommendations. The Task Force was composed of a chair, five additional experts, a methodologist, and a medical writer.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) group, an international group with expertise in development and implementation of evidence-based guidelines. The Task Force used the best available research evidence that members identified to inform the recommendations and consistent language and graphical descriptions of both the strength of a recommendation and the quality of evidence. Consensus was guided by systematic reviews of evidence and discussions.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1&lt;/strong&gt; - Indicates a strong recommendation and is associated with the phrase &quot;The Task Force recommends.&quot;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2&lt;/strong&gt; - Denotes a weak recommendation and is associated with the phrase &quot;The Task Force suggests.&quot;&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guidelines were reviewed and approved sequentially by The Endocrine Society's Clinical Guidelines Subcommittee and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;External reviewers included the leadership of the American Gastroenterological Association Institute and the European Society of Endocrinology.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Definitions for the quality of the evidence (+OOO, ++OO, +++O, and ++++); the strength of the recommendation (1 or 2); and the difference between a &quot;recommendation&quot; and a &quot;suggestion&quot; are provided at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Prevention and Treatment of Weight Regain (WR)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends that a technically proficient surgical team, preferably accredited by a national certifying organization and an integrated medical support team able to provide dietary instruction and behavior modification be available postoperatively and during long-term follow-up (1 | +++O).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends that treatment of WR postoperatively should include a multidisciplinary approach to medical weight loss, including diet instruction, increased activity, behavior modification, and pharmacological therapy (1 | +++O).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force suggests, in cases of severe or unremitting postoperative weight gain, the determination of whether the surgical manipulation of the gastrointestinal tract remains anatomically intact (e.g., absence of gastrogastric fistula after Roux-en-Y gastric bypass [RYGB], integrity of band after a restrictive procedure). If not intact, a multidisciplinary team should consider all options, including patient education, behavior modification, additional weight loss therapies, or referral for revisionary surgery as clinically indicated (2 | +OOO).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Postoperative Nutritional Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends that nutritional management should include an average of 60&amp;ndash;120 g of protein daily in all patients to maintain lean body mass during weight loss and for the long term. This is especially important in those treated with malabsorptive procedures to prevent protein malnutrition and its effects (1 | +++O).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends that long-term vitamin and mineral supplementation be considered in all patients undergoing bariatric surgery, with those who have had malabsorptive procedures requiring potentially more extensive replacement therapy to prevent nutritional deficiencies (1 | +++O).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends periodic clinical and biochemical monitoring (see Table 2 in the original guideline document) for micro- and macronutritional deficiencies after bariatric surgery (1 | +++O).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of Diabetes Mellitus and Lipids&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends that postoperative glycemic control should consist of achieving glycated hemoglobin (Hb) A1c of 7% or less, with fasting blood glucose no greater than 110 mg/dL and postprandial glucose no greater than 180 mg/dL (1 | +++O).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force suggests that physicians and floor nurses be familiar with glycemic targets and insulin protocols, as well as the use of dextrose-free intravenous (iv) fluids and low-sugar liquid supplements (2 | +OOO).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends that obese patients with type 1 diabetes receive scheduled insulin therapy during their hospital stay, as required (1 | +++O).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends that lipid abnormalities should be treated according to the National Cholesterol Education Program (NCEP) guidelines (Adult Treatment Panel III [ATP III]) and that existing lipid-lowering therapy for low-density lipoprotein (LDL)-cholesterol and triglyceride values should be continued after surgery if levels remain above desired goals (1 | +++O).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Bone Health and Gout&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends that patients who have undergone malabsorptive (i.e., RYGB, gastric sleeve [GS], biliopancreatic diversion [BPD]) obesity surgical procedures should have vitamin D, calcium, phosphorus, parathyroid hormone (PTH), and alkaline phosphatase levels followed every 6 months and have a dual-energy x-ray absorptiometry for bone density performed yearly until stable (1 | +++O).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends vitamin D and calcium supplementation postoperatively for malabsorptive obesity surgical procedures and that the doses are adjusted by a qualified medical professional based on serum markers and measures of bone density (1 | +++O).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force suggests that patients with frequent attacks of gout should have prophylactic therapy to lessen the chance of acute gout postoperatively as they lose weight (2 | +OOO).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Gastroenterological and Eating Behavior Considerations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force recommends that bariatric surgery patients should sip fluids in the immediate postoperative period when fully awake after surgery and that they can only be discharged if satisfactorily tolerating oral fluids (1 | +++O).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Particularly after procedures with a gastric restrictive component, the Task Force recommends that gradual progression of food consistency over weeks to months be used to allow patients to adjust to a restrictive meal plan and to minimize vomiting, which can damage surgical anastomoses or lead to gastroesophageal reflux after restrictive procedures (1 | +++O).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force suggests continuous reinforcement of new nutritional habits that discourage the intake of simple carbohydrate-dense foods and beverages to minimize the frequency of bothersome gastrointestinal symptoms due to dumping, including abdominal pain and cramping, nausea, diarrhea, lightheadedness, flushing, tachycardia, and syncope (2 | +OOO).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Task Force suggests that patients who present with postprandial symptoms of hypoglycemia, particularly neuroglycopenic symptoms, should undergo further evaluation for the possibility of insulin-mediated hypoglycemia (2 | +OOO).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;+OOO&lt;/strong&gt; Denotes very low quality evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;++OO&lt;/strong&gt; Denotes low quality evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;+++O&lt;/strong&gt; Denotes moderate quality evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;++++&lt;/strong&gt; Denotes high quality evidence&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1&lt;/strong&gt; - Indicates a strong recommendation and is associated with the phrase &quot;The Task Force recommends.&quot;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2&lt;/strong&gt; - Denotes a weak recommendation and is associated with the phrase &quot;The Task Force suggests.&quot;&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is specifically stated for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate treatment and management of patients who have undergone bariatric surgical procedures may prevent surgical complications and morbidity and mortality associated with these procedures.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Caution must be exercised with the initiation of solutions containing high amounts (&amp;gt;100 to 200 g/d) of dextrose in the setting of severe malnutrition to avoid refeeding syndrome. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Calcium at doses of 300 to 600 mg has a direct dose-related inhibiting effect on iron absorption. This has been seen with calcium carbonate, calcium citrate, and calcium phosphate. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Clinical Practice Guidelines are developed to be of assistance to endocrinologists and other health care professionals by providing guidance and recommendations for particular areas of practice. The Guidelines should not be considered inclusive of all proper approaches or methods, or exclusive of others. The Guidelines cannot guarantee any specific outcome, nor do they establish a standard of care. The Guidelines are not intended to dictate the treatment of a particular patient. Treatment decisions must be made based on the independent judgment of health care providers and each patient's individual circumstances. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Endocrine Society makes no warranty, express or implied, regarding the Guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. The Society shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Linked to each &lt;em&gt;recommendation&lt;/em&gt; is a description of the &lt;em&gt;evidence&lt;/em&gt;, the &lt;em&gt;values&lt;/em&gt; that panelists considered in making the recommendation (when making these explicit was necessary), and &lt;em&gt;remarks&lt;/em&gt;, a section in which panelists offer technical suggestions for testing conditions, dosing, and monitoring. These technical comments reflect the best available evidence applied to a typical patient. Often, this evidence comes from the unsystematic observations of the panelists and should, therefore, be considered suggestions. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Foreign Language Translations" /><FieldValue Value="Patient Resources" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /><FieldValue Value="Safety" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Heber D, Greenway FL, Kaplan LM, Livingston E, Salvador J, Still C, Endocrine Society. Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010 Nov;95(11):4823-43. [248 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21051578&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010 Nov" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="The Endocrine Society - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Endocrine Society&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Endocrine and Nutritional Management of the Post-bariatric Surgery Patient Task Force&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Task Force Members&lt;/em&gt;: David Heber (&lt;em&gt;Chair&lt;/em&gt;); Frank L. Greenway; Lee M. Kaplan; Edward Livingston; Javier Salvador; Christopher Still&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;David Heber, M.D., Ph.D.&lt;/strong&gt; (&lt;em&gt;Chair&lt;/em&gt;)&amp;mdash;Financial or Business/Organizational Interests: Herbalife International; Significant Financial Interest or Leadership Position: Medical Nutrition Council, American Society for Nutrition (Chair, 2006&amp;ndash;2007)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Frank L. Greenway, III, M.D.&lt;/strong&gt;&amp;mdash;Financial or Business/Organizational Interests: ABIC International Consultants, BAROnova, Basic Research Inc., Catalyst Pharmaceutical Partners, General Nutrition Corp., Health and Nutrition Technology, Lipothera, Nastech Pharmaceuticals, Orexigen Therapeutics, GlaxoSmithKline, Leptos Biomedical, Novo Nordisk, Schering-Plough Research Institute; Significant Financial Interest or Leadership Position: Jenny Craig (Chairman)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Lee M. Kaplan, M.D., Ph.D.&lt;/strong&gt;&amp;mdash;Financial or Business/Organizational Interests: Merck Research Labs, GI Dynamics, Johnson &amp;amp; Johnson, Davol, Stryker Development, Gelesis, Blue Cross &amp;amp; Blue Shield; Significant Financial Interest or Leadership Position: none declared&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Edward Livingston, M.D., F.A.C.S.&lt;/strong&gt;&amp;mdash;Financial or Business/Organizational Interests: none declared; Significant Financial Interest or Leadership Position: none declared&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Javier Salvador, M.D., Ph.D.&lt;/strong&gt;&amp;mdash;Financial or Business/Organizational Interests: none declared; Significant Financial Interest or Leadership Position: none declared&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Christopher Still, D.O., M.S.&lt;/strong&gt;&amp;mdash;Financial or Business/Organizational Interests: Ethicon-Endosurgery; Significant Financial Interest or Leadership Position: Obesity Action Coalition, Surgical Review Corp., ABPNS American Board of Physician Nutrition Specialists&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="159" OrdBy="1255" ID="453" Name="Guideline Endorser(s)" Type="orglist"><FieldValue Value="American Gastroenterological Association Institute - Medical Specialty Society" /><FieldValue Value="European Society of Endocrinology - Medical Specialty Society" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from &lt;a href=&quot;https://www.endocrine.org/~/media/endosociety/Files/Publications/Clinical%20Practice%20Guidelines/FINAL-Standalone-Post-Bariatric-Surgery-Guideline-Color.pdf&quot; title=&quot;TES Web site&quot;&gt;The Endocrine Society&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from The Endocrine Society, P.O. Box 17020, Baltimore, MD 21297-1020; Phone: (301) 941-0210; Email: &lt;a href=&quot;mailto:Societyservices@endo-society.org&quot;&gt;Societyservices@endo-society.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patient guide to endocrine and nutritional management after bariatric surgery. Chevy Chase (MD): The Hormone Foundation; 2010 Nov. 2 p. Electronic copies: Available in Portable Document Format (PDF) from &lt;a href=&quot;http://www.hormone.org/patient-guides/2010/bariatric-surgery&quot; title=&quot;The Hormone Foundation Web site&quot;&gt;The Hormone Foundation Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hormones and you. Bariatric surgery and the endocrine system: benefits and risks. Chevy Chase (MD): The Hormone Foundation; 2012 Feb. 2 p. Electronic copies: Available in PDF in English and Spanish from &lt;a href=&quot;http://www.hormone.org/questions-and-answers/2012/bariatric-surgery&quot; title=&quot;The Hormone Foundation Web site&quot;&gt;The Hormone Foundation Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from The Endocrine Society, P.O. Box 17020, Baltimore, MD 21297-1020; Phone: (301) 941-0210; Email: &lt;a href=&quot;mailto:Societyservices@endo-society.org&quot;&gt;Societyservices@endo-society.org&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on April 7, 2011. The information was verified by the guideline developer on June 6, 2011.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is an author manuscript copyrighted by The Endocrine Society. This may not be duplicated or reproduced, other than for personal use or within the rule of &quot;Fair Use of Copyrighted Materials&quot; (section 107, Title 17, U.S. Code) without permission of the copyright owner, The Endocrine Society. From the time of acceptance following peer review, the full text of this manuscript is made freely available by The Endocrine Society at &lt;a href=&quot;http://www.endo-society.org/guidelines/Current-Clinical-Practice-Guidelines.cfm&quot; title=&quot;TES Web site&quot;&gt;http://www.endo-society.org/guidelines/Current-Clinical-Practice-Guidelines.cfm&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
